Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 9 of 9 entries
Sorted by: Best Match Show Resources per page
Prolonged regression of metastatic leptomeningeal breast cancer that has failed conventional therapy: a case report and review of the literature.

Journal of breast cancer

Vincent A, Lesser G, Brown D, Vern-Gross T, Metheny-Barlow L, Lawrence J, Chan M.
PMID: 23593093
J Breast Cancer. 2013 Mar;16(1):122-6. doi: 10.4048/jbc.2013.16.1.122. Epub 2013 Mar 31.

Approximately 5% of breast cancer patients develop leptomeningeal metastases over the course of their disease. Though several treatments options are available for these patients, their prognosis is typically considered to be poor. We report a case of leptomeningeal failure...

Cite
Vincent A, Lesser G, Brown D, et al. Prolonged regression of metastatic leptomeningeal breast cancer that has failed conventional therapy: a case report and review of the literature. J Breast Cancer. 2013;16(1):122-6doi: 10.4048/jbc.2013.16.1.122.
Vincent, A., Lesser, G., Brown, D., Vern-Gross, T., Metheny-Barlow, L., Lawrence, J., & Chan, M. (2013). Prolonged regression of metastatic leptomeningeal breast cancer that has failed conventional therapy: a case report and review of the literature. Journal of breast cancer, 16(1), 122-6. https://doi.org/10.4048/jbc.2013.16.1.122
Vincent, Andrew, et al. "Prolonged regression of metastatic leptomeningeal breast cancer that has failed conventional therapy: a case report and review of the literature." Journal of breast cancer vol. 16,1 (2013): 122-6. doi: https://doi.org/10.4048/jbc.2013.16.1.122
Vincent A, Lesser G, Brown D, Vern-Gross T, Metheny-Barlow L, Lawrence J, Chan M. Prolonged regression of metastatic leptomeningeal breast cancer that has failed conventional therapy: a case report and review of the literature. J Breast Cancer. 2013 Mar;16(1):122-6. doi: 10.4048/jbc.2013.16.1.122. Epub 2013 Mar 31. PMID: 23593093; PMCID: PMC3625760.
Copy Download .nbib Format: NLM
Combined inhibition of AKT and HSF1 suppresses breast cancer stem cells and tumor growth.

Oncotarget

Carpenter RL, Sirkisoon S, Zhu D, Rimkus T, Harrison A, Anderson A, Paw I, Qasem S, Xing F, Liu Y, Chan M, Metheny-Barlow L, Pasche BC, Debinski W, Watabe K, Lo HW.
PMID: 29088759
Oncotarget. 2017 May 22;8(43):73947-73963. doi: 10.18632/oncotarget.18166. eCollection 2017 Sep 26.

Breast cancer is the most common cancer in women and the second leading cause of cancer deaths in women. Over 90% of breast cancer deaths are attributable to metastasis. Our lab has recently reported that AKT activates heat shock...

Cite
Carpenter RL, Sirkisoon S, Zhu D, et al. Combined inhibition of AKT and HSF1 suppresses breast cancer stem cells and tumor growth. Oncotarget. 2017;8(43):73947-73963doi: 10.18632/oncotarget.18166.
Carpenter, R. L., Sirkisoon, S., Zhu, D., Rimkus, T., Harrison, A., Anderson, A., Paw, I., Qasem, S., Xing, F., Liu, Y., Chan, M., Metheny-Barlow, L., Pasche, B. C., Debinski, W., Watabe, K., & Lo, H. W. (2017). Combined inhibition of AKT and HSF1 suppresses breast cancer stem cells and tumor growth. Oncotarget, 8(43), 73947-73963. https://doi.org/10.18632/oncotarget.18166
Carpenter, Richard L, et al. "Combined inhibition of AKT and HSF1 suppresses breast cancer stem cells and tumor growth." Oncotarget vol. 8,43 (2017): 73947-73963. doi: https://doi.org/10.18632/oncotarget.18166
Carpenter RL, Sirkisoon S, Zhu D, Rimkus T, Harrison A, Anderson A, Paw I, Qasem S, Xing F, Liu Y, Chan M, Metheny-Barlow L, Pasche BC, Debinski W, Watabe K, Lo HW. Combined inhibition of AKT and HSF1 suppresses breast cancer stem cells and tumor growth. Oncotarget. 2017 May 22;8(43):73947-73963. doi: 10.18632/oncotarget.18166. eCollection 2017 Sep 26. PMID: 29088759; PMCID: PMC5650314.
Copy Download .nbib Format: NLM
Potential prognostic markers for survival and neurologic death in patients with breast cancer brain metastases who receive upfront SRS alone.

Journal of radiosurgery and SBRT

Shenker RF, Hughes RT, McTyre ER, Lanier C, Lo HW, Metheny-Barlow L, Su J, Thomas A, Brown DR, Avery T, Pasche B, Cramer CK, Laxton AW, Tatter SB, Watabe K, Chan MD.
PMID: 30538888
J Radiosurg SBRT. 2018;5(4):277-283.

PURPOSE/OBJECTIVES: Stereotactic radiosurgery (SRS) is used as a treatment option for breast cancer brain metastases. It is unclear what factors predict neurologic death for these patients.MATERIALS/METHODS: A total of 128 patients with breast cancer brain metastases were treated with...

Cite
Shenker RF, Hughes RT, McTyre ER, et al. Potential prognostic markers for survival and neurologic death in patients with breast cancer brain metastases who receive upfront SRS alone. J Radiosurg SBRT. 2018;5(4):277-283
Shenker, R. F., Hughes, R. T., McTyre, E. R., Lanier, C., Lo, H. W., Metheny-Barlow, L., Su, J., Thomas, A., Brown, D. R., Avery, T., Pasche, B., Cramer, C. K., Laxton, A. W., Tatter, S. B., Watabe, K., & Chan, M. D. (2018). Potential prognostic markers for survival and neurologic death in patients with breast cancer brain metastases who receive upfront SRS alone. Journal of radiosurgery and SBRT, 5(4), 277-283.
Shenker, Rachel F, et al. "Potential prognostic markers for survival and neurologic death in patients with breast cancer brain metastases who receive upfront SRS alone." Journal of radiosurgery and SBRT vol. 5,4 (2018): 277-283.
Shenker RF, Hughes RT, McTyre ER, Lanier C, Lo HW, Metheny-Barlow L, Su J, Thomas A, Brown DR, Avery T, Pasche B, Cramer CK, Laxton AW, Tatter SB, Watabe K, Chan MD. Potential prognostic markers for survival and neurologic death in patients with breast cancer brain metastases who receive upfront SRS alone. J Radiosurg SBRT. 2018;5(4):277-283. PMID: 30538888; PMCID: PMC6255726.
Copy Download .nbib Format: NLM
Pericytes on the tumor vasculature: jekyll or hyde?.

Cancer microenvironment : official journal of the International Cancer Microenvironment Society

Barlow KD, Sanders AM, Soker S, Ergun S, Metheny-Barlow LJ.
PMID: 22467426
Cancer Microenviron. 2013 Apr;6(1):1-17. doi: 10.1007/s12307-012-0102-2. Epub 2012 Mar 31.

The induction of tumor vasculature, known as the 'angiogenic switch', is a rate-limiting step in tumor progression. Normal blood vessels are composed of two distinct cell types: endothelial cells which form the channel through which blood flows, and mural...

Cite
Barlow KD, Sanders AM, Soker S, et al. Pericytes on the tumor vasculature: jekyll or hyde?. Cancer Microenviron. 2012;6(1):1-17doi: 10.1007/s12307-012-0102-2.
Barlow, K. D., Sanders, A. M., Soker, S., Ergun, S., & Metheny-Barlow, L. J. (2013). Pericytes on the tumor vasculature: jekyll or hyde?. Cancer microenvironment : official journal of the International Cancer Microenvironment Society, 6(1), 1-17. https://doi.org/10.1007/s12307-012-0102-2
Barlow, Keith D, et al. "Pericytes on the tumor vasculature: jekyll or hyde?." Cancer microenvironment : official journal of the International Cancer Microenvironment Society vol. 6,1 (2013): 1-17. doi: https://doi.org/10.1007/s12307-012-0102-2
Barlow KD, Sanders AM, Soker S, Ergun S, Metheny-Barlow LJ. Pericytes on the tumor vasculature: jekyll or hyde?. Cancer Microenviron. 2013 Apr;6(1):1-17. doi: 10.1007/s12307-012-0102-2. Epub 2012 Mar 31. PMID: 22467426; PMCID: PMC3601214.
Copy Download .nbib Format: NLM
Pericytes on the tumor vasculature: jekyll or hyde?.

Cancer microenvironment : official journal of the International Cancer Microenvironment Society

Barlow KD, Sanders AM, Soker S, Ergun S, Metheny-Barlow LJ.
PMID: 22467426
Cancer Microenviron. 2013 Apr;6(1):1-17. doi: 10.1007/s12307-012-0102-2. Epub 2012 Mar 31.

The induction of tumor vasculature, known as the 'angiogenic switch', is a rate-limiting step in tumor progression. Normal blood vessels are composed of two distinct cell types: endothelial cells which form the channel through which blood flows, and mural...

Cite
Barlow KD, Sanders AM, Soker S, et al. Pericytes on the tumor vasculature: jekyll or hyde?. Cancer Microenviron. 2012;6(1):1-17doi: 10.1007/s12307-012-0102-2.
Barlow, K. D., Sanders, A. M., Soker, S., Ergun, S., & Metheny-Barlow, L. J. (2013). Pericytes on the tumor vasculature: jekyll or hyde?. Cancer microenvironment : official journal of the International Cancer Microenvironment Society, 6(1), 1-17. https://doi.org/10.1007/s12307-012-0102-2
Barlow, Keith D, et al. "Pericytes on the tumor vasculature: jekyll or hyde?." Cancer microenvironment : official journal of the International Cancer Microenvironment Society vol. 6,1 (2013): 1-17. doi: https://doi.org/10.1007/s12307-012-0102-2
Barlow KD, Sanders AM, Soker S, Ergun S, Metheny-Barlow LJ. Pericytes on the tumor vasculature: jekyll or hyde?. Cancer Microenviron. 2013 Apr;6(1):1-17. doi: 10.1007/s12307-012-0102-2. Epub 2012 Mar 31. PMID: 22467426; PMCID: PMC3601214.
Copy Download .nbib Format: NLM
Correction: Loss of XIST in Breast Cancer Activates MSN-c-Met and Reprograms Microglia via Exosomal miRNA to Promote Brain Metastasis.

Cancer research

Xing F, Liu Y, Wu SY, Wu K, Sharma S, Mo YY, Feng J, Sanders S, Jin G, Singh R, Vidi PA, Tyagi A, Chan MD, Ruiz J, Debinski W, Pasche BC, Lo HW, Metheny-Barlow LJ, D'Agostino RB, Watabe K.
PMID: 34725134
Cancer Res. 2021 Nov 01;81(21):5582. doi: 10.1158/0008-5472.CAN-21-3056.

No abstract available.

Cite
Xing F, Liu Y, Wu SY, et al. Correction: Loss of XIST in Breast Cancer Activates MSN-c-Met and Reprograms Microglia via Exosomal miRNA to Promote Brain Metastasis. Cancer Res. 2021;81(21):5582doi: 10.1158/0008-5472.CAN-21-3056.
Xing, F., Liu, Y., Wu, S. Y., Wu, K., Sharma, S., Mo, Y. Y., Feng, J., Sanders, S., Jin, G., Singh, R., Vidi, P. A., Tyagi, A., Chan, M. D., Ruiz, J., Debinski, W., Pasche, B. C., Lo, H. W., Metheny-Barlow, L. J., D'Agostino, R. B., & Watabe, K. (2021). Correction: Loss of XIST in Breast Cancer Activates MSN-c-Met and Reprograms Microglia via Exosomal miRNA to Promote Brain Metastasis. Cancer research, 81(21), 5582. https://doi.org/10.1158/0008-5472.CAN-21-3056
Xing, Fei, et al. "Correction: Loss of XIST in Breast Cancer Activates MSN-c-Met and Reprograms Microglia via Exosomal miRNA to Promote Brain Metastasis." Cancer research vol. 81,21 (2021): 5582. doi: https://doi.org/10.1158/0008-5472.CAN-21-3056
Xing F, Liu Y, Wu SY, Wu K, Sharma S, Mo YY, Feng J, Sanders S, Jin G, Singh R, Vidi PA, Tyagi A, Chan MD, Ruiz J, Debinski W, Pasche BC, Lo HW, Metheny-Barlow LJ, D'Agostino RB, Watabe K. Correction: Loss of XIST in Breast Cancer Activates MSN-c-Met and Reprograms Microglia via Exosomal miRNA to Promote Brain Metastasis. Cancer Res. 2021 Nov 01;81(21):5582. doi: 10.1158/0008-5472.CAN-21-3056. PMID: 34725134.
Copy Download .nbib Format: NLM
Correction: TGLI1 transcription factor mediates breast cancer brain metastasis via activating metastasis-initiating cancer stem cells and astrocytes in the tumor microenvironment.

Oncogene

Sirkisoon SR, Carpenter RL, Rimkus T, Doheny D, Zhu D, Aguayo NR, Xing F, Chan M, Ruiz J, Metheny-Barlow LJ, Strowd R, Lin J, Regua AT, Arrigo A, Anguelov M, Pasche B, Debinski W, Watabe K, Lo HW.
PMID: 33654200
Oncogene. 2021 Mar;40(12):2338. doi: 10.1038/s41388-020-01620-5.

No abstract available.

Cite
Sirkisoon SR, Carpenter RL, Rimkus T, et al. Correction: TGLI1 transcription factor mediates breast cancer brain metastasis via activating metastasis-initiating cancer stem cells and astrocytes in the tumor microenvironment. Oncogene. 2021;40(12):2338doi: 10.1038/s41388-020-01620-5.
Sirkisoon, S. R., Carpenter, R. L., Rimkus, T., Doheny, D., Zhu, D., Aguayo, N. R., Xing, F., Chan, M., Ruiz, J., Metheny-Barlow, L. J., Strowd, R., Lin, J., Regua, A. T., Arrigo, A., Anguelov, M., Pasche, B., Debinski, W., Watabe, K., & Lo, H. W. (2021). Correction: TGLI1 transcription factor mediates breast cancer brain metastasis via activating metastasis-initiating cancer stem cells and astrocytes in the tumor microenvironment. Oncogene, 40(12), 2338. https://doi.org/10.1038/s41388-020-01620-5
Sirkisoon, Sherona R, et al. "Correction: TGLI1 transcription factor mediates breast cancer brain metastasis via activating metastasis-initiating cancer stem cells and astrocytes in the tumor microenvironment." Oncogene vol. 40,12 (2021): 2338. doi: https://doi.org/10.1038/s41388-020-01620-5
Sirkisoon SR, Carpenter RL, Rimkus T, Doheny D, Zhu D, Aguayo NR, Xing F, Chan M, Ruiz J, Metheny-Barlow LJ, Strowd R, Lin J, Regua AT, Arrigo A, Anguelov M, Pasche B, Debinski W, Watabe K, Lo HW. Correction: TGLI1 transcription factor mediates breast cancer brain metastasis via activating metastasis-initiating cancer stem cells and astrocytes in the tumor microenvironment. Oncogene. 2021 Mar;40(12):2338. doi: 10.1038/s41388-020-01620-5. PMID: 33654200.
Copy Download .nbib Format: NLM
Multi-Omics Analysis of Brain Metastasis Outcomes Following Craniotomy.

Frontiers in oncology

Su J, Song Q, Qasem S, O'Neill S, Lee J, Furdui CM, Pasche B, Metheny-Barlow L, Masters AH, Lo HW, Xing F, Watabe K, Miller LD, Tatter SB, Laxton AW, Whitlow CT, Chan MD, Soike MH, Ruiz J.
PMID: 33889540
Front Oncol. 2021 Apr 06;10:615472. doi: 10.3389/fonc.2020.615472. eCollection 2020.

BACKGROUND: The incidence of brain metastasis continues to increase as therapeutic strategies have improved for a number of solid tumors. The presence of brain metastasis is associated with worse prognosis but it is unclear if distinctive biomarkers can separate...

Cite
Su J, Song Q, Qasem S, et al. Multi-Omics Analysis of Brain Metastasis Outcomes Following Craniotomy. Front Oncol. 2021;10:615472doi: 10.3389/fonc.2020.615472.
Su, J., Song, Q., Qasem, S., O'Neill, S., Lee, J., Furdui, C. M., Pasche, B., Metheny-Barlow, L., Masters, A. H., Lo, H. W., Xing, F., Watabe, K., Miller, L. D., Tatter, S. B., Laxton, A. W., Whitlow, C. T., Chan, M. D., Soike, M. H., & Ruiz, J. (2020). Multi-Omics Analysis of Brain Metastasis Outcomes Following Craniotomy. Frontiers in oncology, 10615472. https://doi.org/10.3389/fonc.2020.615472
Su, Jing, et al. "Multi-Omics Analysis of Brain Metastasis Outcomes Following Craniotomy." Frontiers in oncology vol. 10 (2020): 615472. doi: https://doi.org/10.3389/fonc.2020.615472
Su J, Song Q, Qasem S, O'Neill S, Lee J, Furdui CM, Pasche B, Metheny-Barlow L, Masters AH, Lo HW, Xing F, Watabe K, Miller LD, Tatter SB, Laxton AW, Whitlow CT, Chan MD, Soike MH, Ruiz J. Multi-Omics Analysis of Brain Metastasis Outcomes Following Craniotomy. Front Oncol. 2021 Apr 06;10:615472. doi: 10.3389/fonc.2020.615472. eCollection 2020. PMID: 33889540; PMCID: PMC8056216.
Copy Download .nbib Format: NLM
Hippocampal dose volume histogram predicts Hopkins Verbal Learning Test scores after brain irradiation.

Advances in radiation oncology

Okoukoni C, McTyre ER, Ayala Peacock DN, Peiffer AM, Strowd R, Cramer C, Hinson WH, Rapp S, Metheny-Barlow L, Shaw EG, Chan MD.
PMID: 29204530
Adv Radiat Oncol. 2017 Aug 30;2(4):624-629. doi: 10.1016/j.adro.2017.08.013. eCollection 2017.

PURPOSE: Radiation-induced cognitive decline is relatively common after treatment for primary and metastatic brain tumors; however, identifying dosimetric parameters that are predictive of radiation-induced cognitive decline is difficult due to the heterogeneity of patient characteristics. The memory function is...

Cite
Okoukoni C, McTyre ER, Ayala Peacock DN, et al. Hippocampal dose volume histogram predicts Hopkins Verbal Learning Test scores after brain irradiation. Adv Radiat Oncol. 2017;2(4):624-629doi: 10.1016/j.adro.2017.08.013.
Okoukoni, C., McTyre, E. R., Ayala Peacock, D. N., Peiffer, A. M., Strowd, R., Cramer, C., Hinson, W. H., Rapp, S., Metheny-Barlow, L., Shaw, E. G., & Chan, M. D. (2017). Hippocampal dose volume histogram predicts Hopkins Verbal Learning Test scores after brain irradiation. Advances in radiation oncology, 2(4), 624-629. https://doi.org/10.1016/j.adro.2017.08.013
Okoukoni, Catherine, et al. "Hippocampal dose volume histogram predicts Hopkins Verbal Learning Test scores after brain irradiation." Advances in radiation oncology vol. 2,4 (2017): 624-629. doi: https://doi.org/10.1016/j.adro.2017.08.013
Okoukoni C, McTyre ER, Ayala Peacock DN, Peiffer AM, Strowd R, Cramer C, Hinson WH, Rapp S, Metheny-Barlow L, Shaw EG, Chan MD. Hippocampal dose volume histogram predicts Hopkins Verbal Learning Test scores after brain irradiation. Adv Radiat Oncol. 2017 Aug 30;2(4):624-629. doi: 10.1016/j.adro.2017.08.013. eCollection 2017. PMID: 29204530; PMCID: PMC5707405.
Copy Download .nbib Format: NLM
Showing 1 to 9 of 9 entries